SEARCH

SEARCH BY CITATION

References

  • 1
    Burt CW, Schappert SM: Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1999–2000. Vital Health Stat 2004; 13: 178.
  • 2
    Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, et al.: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the Adult. Circulation 2005; 112: 18251852.
  • 3
    Adams KF, Lindenfeld J, Arnold JMO, Baker DW, Barnard DH, et al.: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 2006; 12: e1e122.
  • 4
    Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525533.
  • 5
    Ahmad A, Rich MW, Love TE, Lloyd-Jones DM, Aban IB, et al.: Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006; 27: 178186.
  • 6
    Taylor AL, Zieche S, Yancy C, Carson P, D'Agostino R, et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351: 20492057.
  • 7
    Neuberg GW, Miller AB, O'Connor CM, Belkin RN, Carson PE, et al.: Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002; 144: 3138.
  • 8
    Emerman CL, DeMarco T, Costanzo MR, Peacock WF: Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE® Registry [abstract 368]. J Card Fail 2004; 10(4, suppl 1): S116S117.
  • 9
    Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, et al.: Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003; 42: 705708.
  • 10
    Domanski M, Tian X, Haigney M, Pitt B: Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail 2006; 12: 327332.
  • 11
    Fonarow GC: Pharmacologic therapies for acutely decompensated heart failure. Rev Cardiovasc Med 2002; 3(suppl 4): S18S27.
  • 12
    Elis A, Bental T, Kimchi O, Ravid M, Lishner M: Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study. Clin Pharmacol Ther 1998; 63: 682685.
  • 13
    Cuffe MS, Califf RM, Adams KFJ, Benza R, Bourge R, et al.: Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287: 15411547.
  • 14
    Mills RM, Hobbs RE, Young JB: ”BNP” for heart failure: role of nesiritide in cardiovascular therapeutics. Congest Heart Fail 2002; 8: 270273.
  • 15
    Peacock FW, Emerman CL, Diercks DB, Lopatin M, Fonarow GC: Acute heart failure mortality is dependent on time to intravenous vasoactive administration [abstract 386]. J Card Fail 2006; 12(6, suppl 1): S117.
  • 16
    Franci GS: Vasodilators in the intensive care unit. Am Heart J 1991; 121: 18751878.
  • 17
    Cioffi G, Stefenelli C, Tarantini L, Opasich C: Hemodynamic response to intensive unloading therapy (furosemide and nitroprusside) in patients > 70 years of age with left ventricular systolic dysfunction and decompensated chronic heart failure. Am J Cardiol 2003; 92(9): 10501056.
  • 18
    Johnson W, Omland T, Hall C, Lucas C, Myken A: Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 2002; 39: 16231629.
  • 19
    Abraham WT, Lowes BD, Ferguson DA, Odom J, Kim JK, et al.: Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998; 4: 3744.
  • 20
    Aronson D, Burger AJ: Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failure. Am Heart J 2004; 148: 920926.
  • 21
    Sica DA, Gottwald MD, Li Yu-Ping: Nesiritide appears to inhibit the rise in plasma aldosterone associated with furosemide diuresis [abstract 275]. J Card Fail 2006; 12(6, suppl 1): S85S86.
  • 22
    Jensen KT, Carstens J, Pedersen EB: Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol 1998; 274: F63F72.
  • 23
    Michaels AD, Klein A, Chatterjee Ku: Effects of intravenous nesiritide on coronary vasomotor regulation and myocardial oxygen extraction. J Am Coll Cardiol 2003; 41(6): 205.
  • 24
    Publication Committee for the VMAC Investigators: Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287: 15311540.
  • 25
    Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K: Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005; 293: 19001905.
  • 26
    Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ: Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005; 293: 572580.
  • 27
    Mentzer RM Jr, Oz MC, Sladen RN, Graeve AH, Hebeler RF, et al.: Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA trial. J Am Coll Cardiol 2007; 49(6):Available at: http://content.onlinejacc.org/in_press_ fasttrack.dtl, Accessed December 11, 2006.
  • 28
    Mebazaa A, Nieminem MS, Packer M, Cohen-Solal A, Kleber FX, et al.: Levosimendan versus Dobutamine for patients with acute decompensated heart failure The SURVIVE Randomized Trial. JAMA 2007; 297: 18831891.
  • 29
    Di Donato M, Toso A, Dor V, Sabatier M, Barletta G, et al.: Surgical ventricular restoration improves mechanical intraventricular dyssynchrony in ischemic cardiomyopathy. Circulation 2004; 109: 25362543.
  • 30
    National Heart, Lung, and Blood Institute: Surgical Treatment for Ischemic Heart Failure (STICH). National Institute of Health website. Available at: http://www.clinicaltrials.gov/ct/show/NCT00023595. Updated 2005; accessed March 21, 2005.
  • 31
    Mehta SM, Pae WE Jr, Rosenberg G, Snyder AJ, Weiss WJ, et al.: The LionHeart LVD-2000: a completely implanted left ventricular assist device for chronic circulatory support. Ann Thorac Surg 2001; 71: S156S161.
  • 32
    Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, et al.: Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345: 14351443.
  • 33
    Abraham WT, Hayes DL: Cardiac resynchronization therapy for heart failure. Circulation 2003; 108: 25962603.
  • 34
    Blanc J-J, Bertault-Valls V, Fatemi M, Gilard M, Pennec PY, et al.: Midterm benefits of left univentricular pacing in patients with congestive heart failure. Circulation 2004; 109: 17411744.
  • 35
    Bradley DJ, Bradley EA, Baughman KL, Berger RD, Calkins H, et al.: Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA 2003; 289: 730740.
  • 36
    Salukhe TV, Dimopoulos K, Francis D: Cardiac resynchronisation may reduce all-cause mortality: meta-analysis of preliminary COMPANION data with CONTAK-CD, InSync ICD, MIRACLE and MUSTIC [editorial]. Int J Cardiol 2004; 93: 101103.
  • 37
    Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, et al.: Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 21402150.
  • 38
    Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, et al.: The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 15391549.
  • 39
    Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, et al.: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225237.
  • 40
    Costanzo MR, Saltzberg M, O'Sullivan J, Sobotka P: Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol 2005; 46 20472051.
  • 41
    Lopez-Candales AL, Carron C, Schwartz J: Need for hospice and palliative care services in patients with end-stage heart failure treated with intermittent infusion of inotropes. Clin Cardiol 2004; 27: 2328.